One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL409116 Compound in Healthy Volunteers
Latest Information Update: 17 May 2022
Price :
$35 *
At a glance
- Drugs CPL 409116 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Celon Pharma
- 24 Mar 2022 Status changed from recruiting to completed.
- 10 Feb 2021 According to a Celon Pharma media release, it has successfully completed Phase 1A of this trial .Celon plans to initiate a multiple ascending dose Phase 1b study with safety, pharmacokinetic and pharmacodynamic evaluations in the next coming weeks and expects readouts from this study to be available at the end of 2Q 2021
- 10 Feb 2021 Results published in the Media Release